EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

Glasgow, Scotland – 7th September 2021 –EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.

Read full release here.